Latest News
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
14 November 2025 - US-based based generic pharmaceutical company Ingenus Pharmaceuticals announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for its Conjugated Estrogens Tablets, USP, the first FDA-appro...
Eisai and BioArctic's Leqembi gains UK regulatory approval for IV maintenance treatment of Alzheimer's disease
14 November 2025 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its Japanese partner Eisai Co Ltd (TYO:4523) announced on Thursday that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Le...
IVI RMA Global Expands Footprint with Acquisition of ART Fertility Clinics, Establishing Middle East as Fifth Operating Region
14 November 2025 - IVI RMA Global, recognised as the world's leading reproductive medicine platform, has confirmed that following the completion of its acquisition of ART Fertility Clinics ("ART Fertility") -- operating in the United A...
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
13 November 2025 - Chinese biotechnology company Ascletis Pharma Inc (HKEX:1672) announced on Wednesday the co-formulation of ASC36, a once-monthly next-generation amylin receptor agonist, and ASC35, a once-monthly next-generation GLP-1R/GIPR dual ag...
EirGenix signs second global exclusive licensing deal with Sandoz
13 November 2025 - Taiwan-based contract development and manufacturing organisation EirGenix Inc (TWSE:6589) announced on Wednesday that it has signed a second global exclusive licensing agreement with Sandoz AG (SIX:SDZ) (OTCQX:SDZNY), a Swiss compa...